TREATMENT
Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in chronic obstructive pulmonary disease
| The first 150 words of the full text of this article appear below. |
In patients with stable chronic obstructive pulmonary disease (COPD), what are the harms and benefits of inhaled corticosteroid (ICS) therapy?
Included studies compared an ICS with placebo or other inhaled medications in patients
40 years of age with stable COPD. Outcomes were all-cause mortality at 1 and 3 years, pneumonia, and fractures.
Medline, EMBASE/Excerpta Medica, Cochrane Central Register of Controlled Trials, CINAHL, Web of Science, and PsycINFO (to Feb 2008); and references were searched for published, double-blind, randomised controlled trials (RCTs) with duration
6 months. 11 RCTs (14 comparisons, n = 14 426) met the selection criteria. 8 comparisons were placebo controlled; most other trials compared an ICS plus a long-acting β2 agonist (LABA) with the LABA alone. 7 trials reported concealment of allocation, and all trials had blinding of outcome assessors. Mean study duration was 24 months (range 6–40 mo).
ICS therapy did not reduce mortality at any time
University of Buffalo, Buffalo, New York, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
